From micrographia to Parkinson's disease dysgraphia.

Letanneux A, Danna J, Velay JL, Viallet F, Pinto S.

Mov Disord. 2014 Oct;29(12):1467-75. doi: 10.1002/mds.25990. Review.

Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration.

Ayton S, Lei P.

Biomed Res Int. 2014;2014:581256. doi: 10.1155/2014/581256. Review.

Pull test performance and correlation with falls risk in Parkinson's disease.

Munhoz RP, Teive HA.

Arq Neuropsiquiatr. 2014 Aug;72(8):587-91.

MTHFR C677T variant reduces risk of sporadic Parkinson's disease in ethnic Chinese.

Liao Q, Li NN, Mao XY, Chang XL, Zhao DM, Zhang JH, Yu WJ, Tan EK, Peng R.

Acta Neurol Scand. 2014 Jul;130(1):e30-4. doi: 10.1111/ane.12245.

Comorbidity and functional mobility in persons with Parkinson disease.

King LA, Priest KC, Nutt J, Chen Y, Chen Z, Melnick M, Horak F.

Arch Phys Med Rehabil. 2014 Nov;95(11):2152-7. doi: 10.1016/j.apmr.2014.07.396.

Interventions that improve body and brain bioenergetics for Parkinson's disease risk reduction and therapy.

Mattson MP.

J Parkinsons Dis. 2014;4(1):1-13. doi: 10.3233/JPD-130335. Review.

Prospective memory performance of patients with Parkinson's disease depends on shifting aptitude: evidence from cognitive rehabilitation.

Costa A, Peppe A, Serafini F, Zabberoni S, Barban F, Caltagirone C, Carlesimo GA.

J Int Neuropsychol Soc. 2014 Aug;20(7):717-26. doi: 10.1017/S1355617714000563.

A conditioned response as a measure of impulsive-compulsive behaviours in Parkinson's disease.

Evans AH, Kettlewell J, McGregor S, Kotschet K, Griffiths RI, Horne M.

PLoS One. 2014 Feb 24;9(2):e89319. doi: 10.1371/journal.pone.0089319.

Impulse control and repetitive behaviors in Parkinson's disease - are there differences in the relation to dopamine agonist treatment?

Somme JH, Gómez-Esteban JC, Tijero B, Berganzo K, Lezcano E, Zarranz JJ.

J Neurol Sci. 2014 Oct 15;345(1-2):252-3. doi: 10.1016/j.jns.2014.07.004. No abstract available.

n-butylidenephthalide protects against dopaminergic neuron degeneration and α-synuclein accumulation in Caenorhabditis elegans models of Parkinson's disease.

Fu RH, Harn HJ, Liu SP, Chen CS, Chang WL, Chen YM, Huang JE, Li RJ, Tsai SY, Hung HS, Shyu WC, Lin SZ, Wang YC.

PLoS One. 2014 Jan 8;9(1):e85305. doi: 10.1371/journal.pone.0085305.

ERKed by LRRK2: a cell biological perspective on hereditary and sporadic Parkinson's disease.

Verma M, Steer EK, Chu CT.

Biochim Biophys Acta. 2014 Aug;1842(8):1273-81. doi: 10.1016/j.bbadis.2013.11.005. Review.

Targeting GTPases in Parkinson's disease: comparison to the historic path of kinase drug discovery and perspectives.

Hong L, Sklar LA.

Front Mol Neurosci. 2014 Jun 5;7:52. doi: 10.3389/fnmol.2014.00052. Review.

Exenatide as a potential treatment for patients with Parkinson's disease: first steps into the clinic.

Foltynie T, Aviles-Olmos I.

Alzheimers Dement. 2014 Feb;10(1 Suppl):S38-46. doi: 10.1016/j.jalz.2013.12.005. Review.

Uneven age effects of [(18)F]FP-CIT binding in the striatum of Parkinson's disease.

Lee CS, Kim SJ, Oh SJ, Kim HO, Yun SC, Doudet D, Kim JS.

Ann Nucl Med. 2014 Nov;28(9):874-9. doi: 10.1007/s12149-014-0882-1.

α-Synuclein and mitochondrial bioenergetics regulate tetrahydrobiopterin levels in a human dopaminergic model of Parkinson disease.

Ryan BJ, Lourenço-Venda LL, Crabtree MJ, Hale AB, Channon KM, Wade-Martins R.

Free Radic Biol Med. 2014 Feb;67:58-68. doi: 10.1016/j.freeradbiomed.2013.10.008.